Todas las investigaciones
ReclutamientoOBSERVACIONAL

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

This study, called ReCySOHT, is looking back at the medical records of adults who have had a solid organ transplant (like a kidney or heart transplant) or a blood stem cell transplant. We're focusing on patients who developed a Cytomegalovirus (CMV) infection that didn't respond well to ganciclovir, a standard medicine. Doctors want to understand why some people get this type of CMV infection and what factors might increase their risk. By looking at information from many patients, the study hopes to find common patterns. The goal is to help healthcare teams better prevent and treat these challenging CMV infections, ultimately improving care for transplant recipients.

De un vistazo

Estado
Reclutamiento
Patrocinador
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Objetivo de inscripción
100
Inicio
19 Jun 2023
Estimación de finalización
28 Feb 2028

¿De qué trata este estudio?

When you have an organ transplant or a stem cell transplant, your immune system is often weaker to prevent your body from rejecting the new organ or cells. This can make you more vulnerable to infections, like Cytomegalovirus, or CMV. CMV is a common virus that can cause serious problems for transplant patients.

Usually, doctors use a medicine called ganciclovir to treat or prevent CMV infections. It's generally very effective and safe. However, sometimes the CMV infection doesn't respond to ganciclovir, either because the virus becomes resistant to the drug, or it just doesn't clear up. This is called ganciclovir-resistant or refractory (GCV-RR) CMV, and it can be a serious problem because there are fewer treatment options, and they can have more side effects. It's important for doctors to understand why this happens and who might be at higher risk.

This study is looking back at information from many transplant patients to gather more details about these specific CMV infections. By carefully reviewing existing medical records, researchers hope to identify common factors or situations that lead to ganciclovir-resistant CMV. This knowledge will be crucial for developing better ways to prevent these difficult infections and improve treatment strategies for patients in the future.

Puntos clave

  • Study examines past medical records of transplant patients.
  • Focuses on a difficult-to-treat CMV infection (ganciclovir-resistant).
  • Aims to find risk factors for this type of infection.
  • No new treatments or tests for participants.
  • Information gained could improve future patient care.
  • Your data will be anonymous and confidential.

¿Quién puede ser elegible?

To be included in this study, you would be an adult, aged 18 or older, who has received either a solid organ transplant (like a kidney, heart, or liver) or a blood (stem cell) transplant. You would also have experienced a CMV infection that was treated with specific medicines called ganciclovir or valganciclovir.

Because this is a study looking at past medical records, researchers need to be able to find certain information in your charts. For example, they need to know details about your transplant, like if there was a good match between your body and the donor, and how you recovered after both your CMV infection and your transplant.

You wouldn't be part of this study if some of this important medical information is missing from your records, as researchers wouldn't be able to get a complete picture of your situation. For instance, if they can't find clear notes about your CMV infection, details about the donor match, or how you were doing 30, 60, or 90 days after your CMV was diagnosed, then you wouldn't be included.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Have you had an organ or stem cell transplant?
  3. Did you get a CMV infection after your transplant?
  4. Was your CMV infection treated with ganciclovir or valganciclovir?
  5. Are your medical records complete regarding your transplant and CMV treatment?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

This study is a bit different because it's a "retrospective observational study." This means researchers are looking back at information that has already been collected in your past medical records. You won't need to attend any extra appointments, take new medicines, or undergo any additional tests. Your participation simply involves allowing the research team to review your existing health information to help them learn more about CMV infections in transplant patients. There are no direct visits or follow-up actions required from you.

Riesgos y beneficios potenciales

Since this study only involves looking at existing medical records, there are no physical risks or direct benefits to you as a participant. Your medical care will not change in any way. The potential benefit is to future patients; the information gathered from your anonymised data, combined with that of others, could help doctors better prevent and treat difficult CMV infections in transplant recipients. You have the right to withdraw your consent for your data to be used at any time without affecting your medical treatment.

Ubicaciones (23)

  • MD Anderson Cancer Center
    Código postal verificado
    Houston, Estados Unidos· Aún no reclutando
  • Instituto Jules Bordet
    Código postal verificado
    Bruselas, Bélgica· Aún no reclutando
  • University Hospitals Leuven
    Código postal verificado
    Lovaina, Bélgica· Aún no reclutando
  • Helsinki University Central Hospital
    Código postal verificado
    Helsinki, Finland· Aún no reclutando
  • Centre Hospitalier Universitaire de Limoges
    Código postal verificado
    Limoges, France· Aún no reclutando
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna
    Código postal verificado
    Bologna, Italy· Reclutamiento
  • Humanitas Research Hospital
    Código postal verificado
    Rozzano, Italy· Aún no reclutando
  • Istituto mediterraneo per i trapianti e terapie ad alta specializzazione (ISMETT)
    Código postal verificado
    Palermo, Italy· Reclutamiento
  • Ospedale San Martino
    Código postal verificado
    Genova, Italy· Aún no reclutando
  • Policlinico di Milano
    Código postal verificado
    Milan, Italy· Reclutamiento
  • Azienda Ospedaliero-Universitaria di Modena
    Código postal verificado
    Módena, Italia· Reclutamiento
  • Azienda Ospedaliera dei Colli
    Código postal verificado
    Nápoles, Italia· Aún no reclutando

Preguntas comunes

What is CMV and why is it important for transplant patients?

CMV is a common virus that can cause serious illness in people with weakened immune systems, such as those who have received an organ or stem cell transplant.

What does 'ganciclovir-resistant' mean?

It means the CMV infection didn't respond well to ganciclovir, a standard medicine usually used to treat it, making the infection harder to clear.

Will this study affect my current medical care?

No, this study only looks at past medical records. It will not change your current or future medical care in any way.

¿Se mantiene privada mi información personal?

Yes, all data collected for the study will be treated confidentially, and your personal details will be anonymised to protect your privacy.

Who is conducting this study?

The ReCySOHT study is being conducted by multiple medical centres, aiming to gather a broad range of information on CMV infections.

Cómo obtener más información

Renato Pascale, MD

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "Ganciclovir Resistant/Refractory Cytomegalovirus Infection i…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.